Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Total Liabilities
Everything the company owes to creditors and other parties.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 49.8% from a year ago
Total liabilities stood at $18.86M at the end of Q1 FY2026, down 49.8% from a year earlier and down 14.4% from the prior quarter. Over 3 fiscal years it compounded at -52.8% a year.
Context
- Total liabilities amounted to 7.5% of total assets at the end of Q1 FY2026, down 22.4 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -49.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.02M USD
- Year-over-year change
- -26.8%
- 4-year CAGR
- -41.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.02M | -26.8% |
| FY2024 | 2024-12-31 | 30.1M | +14.6% |
| FY2023 | 2023-12-31 | 26.27M | -87.5% |
| FY2022 | 2022-12-31 | 210.03M | +9.1% |
| FY2021 | 2021-12-31 | 192.46M | — |
Total Liabilities vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's Mar 2026 total liabilities of $18.86M is the 9th highest of the 11 companies compared; the peer median is $54.49M.
- Its year-over-year change of -49.8% is the 10th highest of 11, against a peer median of +15.3%.
- Total liabilities amounts to 7.5% of total assets for LXEO, versus a peer median of 22.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $196.35M | +7.9% | -10.1% | 30.4% | |
| Mar 2026 | $152.76M | +26.8% | +14.8% | 35.2% | |
| Mar 2026 | $65.72M | -77.9% | -6.8% | 57.1% | |
| Mar 2026 | $61.44M | +67.7% | +44.9% | 23.9% | |
| Mar 2026 | $58.5M | +22.7% | +7.6% | 22.0% | |
| Mar 2026 | $50.48M | +94.9% | +63.5% | 24.2% | |
| Mar 2026 | $47.58M | +82.2% | +9.4% | 14.6% | |
| Mar 2026 | $45.66M | -43.3% | -17.6% | 20.8% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $18.86M | -49.8% | -52.8% | 7.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $11.31M | -16.2% | +11.3% | 4.3% |
| Mar 2026 | $6.56M | -20.4% | -42.3% | 16.2% | |
| Peer median (excluding LXEO) | $54.49M | +15.3% | +8.5% | 22.9% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 135.86M | 77.34M | 121.47M | 35.01M | 63M |
| Short-term Investments | 0 | 0 | 0 | 86.5M | 118.77M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 696K | 371K | 3K | 4.6M | 6.63M |
| Total Current Assets | 136.68M | 80.05M | 124.29M | 126.12M | 188.39M |
| Property, Plant & Equipment (Net) | 174K | 13.78M | 12.26M | 10.56M | 8.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 7.01M | 68.19M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2K | 7.49M | 3.25M | 3.25M | 3.25M |
| Total Non-current Assets | 176K | 21.26M | 15.51M | 20.82M | 80.3M |
| Total Assets | 136.86M | 97.08M | 139.81M | 146.94M | 268.69M |
| Account Payables | 3.06M | 2.68M | 3.79M | 6.42M | 4.86M |
| Short-term Debt | 0 | 0 | 0 | 2.67M | 0 |
| Tax Payables | 528K | 506K | 157K | 0 | 0 |
| Deferred Revenue | 46K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 961K | 2.15M | 3.36M | 4.66M | 4.14M |
| Total Current Liabilities | 7.45M | 14.35M | 17.24M | 22.85M | 16.81M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 185.01M | 185.03M | 0 | 0 | 0 |
| Total Non-current Liabilities | 185.01M | 195.68M | 9.03M | 7.25M | 5.21M |
| Total Liabilities | 192.46M | 210.03M | 26.27M | 30.1M | 22.02M |
| Common Stock | 1.68K | 0 | 3K | 3K | 7K |
| Retained Earnings | (56.17M) | (115.45M) | (181.84M) | (280.17M) | (380.13M) |
| Accumulated OCI | (185.01M) | (185.03M) | 0 | (103K) | 188K |
| Other Stockholders Equity | 863 | 185.03M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (55.6M) | (112.95M) | 113.54M | 116.84M | 246.67M |
| Total Debt | 0 | 13.48M | 11.64M | 9.92M | 7.89M |
| Net Debt | (135.86M) | (63.85M) | (109.83M) | (25.09M) | (55.11M) |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.